Diabetic Gastroparesis Treatment

Global Diabetic Gastroparesis Treatment Market to Reach US$2.7 Billion by 2030

The global market for Diabetic Gastroparesis Treatment estimated at US$2.3 Billion in the year 2024, is expected to reach US$2.7 Billion by 2030, growing at a CAGR of 2.6% over the analysis period 2024-2030. Drugs, one of the segments analyzed in the report, is expected to record a 3.3% CAGR and reach US$1.7 Billion by the end of the analysis period. Growth in the Surgical Treatment Products segment is estimated at 1.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$622.2 Million While China is Forecast to Grow at 5.2% CAGR

The Diabetic Gastroparesis Treatment market in the U.S. is estimated at US$622.2 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$519.7 Million by the year 2030 trailing a CAGR of 5.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.0% and 2.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.4% CAGR.

Global Diabetic Gastroparesis Treatment Market – Key Trends & Drivers Summarized

Is Therapeutic Innovation Catching Up With an Underdiagnosed Condition?
Diabetic gastroparesis—a chronic gastric motility disorder caused by long-term diabetes—remains one of the most underdiagnosed and difficult-to-treat complications of diabetes. It primarily affects individuals with Type 1 and long-standing Type 2 diabetes, leading to delayed gastric emptying, nausea, vomiting, bloating, and impaired glycemic control. The global diabetic gastroparesis treatment market is now undergoing a transformation, driven by growing disease awareness, diagnostic improvements, and the introduction of novel prokinetic therapies.

One of the most significant trends is the transition from symptomatic treatment to targeted motility-modulating agents. Historically managed with dietary modifications, antiemetics, and off-label use of prokinetics, the market is now witnessing a resurgence in pharmaceutical R&D focused on selective serotonin receptor agonists, ghrelin receptor agonists, and CGRP antagonists. These innovations aim to address the underlying pathophysiology of impaired gastric motility rather than merely suppress symptoms.

How Is R&D Reshaping the Therapeutic Landscape for Gastroparesis?
Traditional treatment approaches have long relied on metoclopramide, domperidone, erythromycin, and ondansetron. However, their long-term use is limited by adverse effects such as extrapyramidal symptoms, QT prolongation, and tachyphylaxis. In response, pharmaceutical companies are developing more targeted, better-tolerated prokinetic agents. Promising candidates include relamorelin, a ghrelin receptor agonist that enhances gastric emptying and shows potential in reducing symptom severity with fewer CNS side effects.

Other drugs in clinical trials include velusetrag (5-HT4 agonist) and camicinal, both designed to selectively stimulate gastrointestinal motility without cardiovascular or neurological risks. Additionally, botulinum toxin injections into the pyloric sphincter and gastric electrical stimulation are being explored as interventional options for refractory cases. These advancements are shifting the focus toward personalized, mechanism-based therapies, particularly for patients with severe symptoms and delayed gastric emptying confirmed by gastric scintigraphy.

Where Is Demand Emerging and Who Are the Primary Stakeholders?
The diabetic gastroparesis treatment market is concentrated in regions with high diabetes prevalence—particularly in North America, Western Europe, China, and India. The U.S. leads the market in terms of both diagnosis rates and treatment adoption due to greater access to motility testing and specialized gastroenterology services. However, underdiagnosis remains a major hurdle globally, as symptoms often overlap with other gastrointestinal conditions and lack standardized evaluation protocols.

Endocrinologists, gastroenterologists, and diabetologists are key prescribers, with treatment decisions often requiring multidisciplinary coordination. Academic medical centers and tertiary referral hospitals play a crucial role in diagnosing and managing severe cases, while pharmaceutical companies are working closely with these institutions to conduct clinical trials and expand therapeutic indications. Moreover, diabetic patient advocacy groups and telemedicine platforms are contributing to earlier recognition of symptoms, thereby improving treatment access and adherence.

What’s Driving Growth in the Diabetic Gastroparesis Treatment Market?
The growth in the diabetic gastroparesis treatment market is driven by several factors tied to diabetes incidence, unmet clinical need, and emerging pharmacological solutions. The global rise in diabetes—particularly in younger adults and the aging population—has significantly expanded the potential patient pool for gastroparesis, especially in poorly managed or insulin-dependent cases. Increasing awareness and availability of gastric motility diagnostics are also improving detection and differentiation from other GI disorders.

Pharmaceutical innovation is a key growth driver, with new classes of prokinetics and symptom-targeted therapies entering late-stage clinical development. These agents offer improved tolerability and efficacy, positioning them as safer long-term solutions in a field previously dominated by off-label and side-effect-prone treatments. Additionally, improvements in health insurance coverage for diagnostic tests and specialty consultations are aiding market penetration in developed countries.

The convergence of digital health tools—including remote symptom tracking apps, wearable glycemic monitors, and AI-assisted dietary management platforms—is also fostering more individualized treatment plans. These technological integrations, along with targeted education campaigns and expanding clinical trials, are reshaping how diabetic gastroparesis is understood, managed, and monetized across global healthcare systems.

SCOPE OF STUDY:

The report analyzes the Diabetic Gastroparesis Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Product Type (Drugs, Surgical Treatment Products); Disease Indication (Compensated Gastroparesis, Gastric Failure); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

• Abbott Laboratories
• AbbVie Inc.
• Alfa Wassermann S.p.A.
• AstraZeneca plc
• Bausch Health Companies Inc.
• Bayer AG
• Boston Scientific Corporation
• C. R. Bard, Inc. (BD)
• Cardinal Health, Inc.
• Cipla Limited
• Evoke Pharma, Inc.
• GlaxoSmithKline plc
• Janssen Global Services, LLC
• Medtronic plc
• Neurogastrx, Inc.
• Pfizer Inc.
• Rhythm Pharmaceuticals, Inc.
• Takeda Pharmaceutical Company Limited
• Teva Pharmaceutical Industries Ltd.
• Vanda Pharmaceuticals, Inc.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.